

## Fax Page 1 To:

# Island County Health Department

(360) 221-8480 (Confidential FAX line)

Adapted from WA DOH Form 347-102

CONFIDENTIAL SEXUALLY TRANSMITTED INFECTION CASE REPORT Report STIs within 3 work days (WAC 246-101-101/301)

PATIENT INFO	PATIENT INFORMATION												
LAST NAME FII			IRST NAME			MIDDLE NAME		DAT	DATE OF BIRTH				
									мо		DAY	-	YR
ADDRESS (	Unhoused or	unstably housed i	n the pasi	t 3 months	s) C	ITY				STATE		ZIP CODI	E
TELEPHONE		EMAIL		EN	GLISH	SPEAKING	G? 🗌 Yes 🔲 N	o *instructio	ns on D	IAGNOS	IS DA	TE.	
( )							e (Code*: L	pg. 5		10 I	DA	γ	YR
SEX ASSIGNED	GENDER IDENT	TITY		ETHNICITY			RACE CATEGO		II that	apply)*:		*Ins	structions on page 3
AT BIRTH ☐ Male ☐ Transgender M			er MTF	ITF ☐ Hispanic or Latina/o/x ☐ White				-	Asian				
☐ Male				□ Non-Hispanic □ Black □ American Indian / A				ndian / Ala	☐ Other Naska Native ☐ Unknown				
☐ Female								☐ American Indian / Alaska Native ☐ Unknown ☐ Native Hawaiian / Other Pacific Islander ☐ Refused					
☐ Intersex    Genderqueer  ☐ Refused   ☐ Refused				Refused EXTENDED RACE COD				DE(S)*: R R R R					
CURRENTLY	REASON FOR E	XAM (check one):	GENDE	FR OF SEX	PΔRTN	FRS (check		HIV STAT		*Submit HIV			CURRENTLY
PREGNANT? Exposed to Inf				DER OF SEX PARTNERS (check a ale						7/1103	case Report	ON PrEP?	
☐ Yes	☐ Symptomatic		Female			☐ Transgender FTM		☐ New HIV diagnosis at this visit*		visit*	☐ Yes		
□No		n (No Symptoms)	s) Nonbinary /			Other	Other		gative HIV test at this visit				
☐ Unk. ☐ NA			Genderqueer 🗆 Unknown				☐ Did n	Did not test (unknown status)					
DIAGNOSIS - D													
GONORRHEA (la		CITEC (all that			/ -				YPHILI				
DIAGNOSIS (che ☐ Asymptomatic		SITES (all that apply):		TREATMENT (check all prescribed):  ☐ Ceftriaxone: ☐ 250 mg ☐ 500 mg ☐ 1 g				STAGE (check one):  Primary (Chancre, etc.)					
Symptomatic,		· = :		☐ Ceffixime		☐ 400 mg	,		Secondary (Rash, etc.)				
Pelvic Inflamn	matory Disease	Urine		☐ Azithromycin: ☐ 1 g ☐ 2 g				☐ Early Latent (< 1 year)					
☐ Ophthalmia☐ Disseminated	l	Rectum		☐ Doxycycline: ☐ 100 mg BID x 7 days					☐ Unknown Duration or Late☐ Congenital				
☐ Other Compli		Pharynx □ Vagina		☐ Gentamicin: ☐ 240 mg ☐ Gemifloxacin: ☐ 320 mg									
		Ocular		! Other:					MANIFESTATIONS (check all that apply):				
Date Tested:		Other:			e Prescribed:				□ Neurologic □ Otic □ Ocular □ Tertiary				
CHLAMYDIA (la	b confirmed)							TREATMENT (check one):					
DIAGNOSIS (check one)		SITES (all that apply):					E	Bicillin L - A: 2.4 MU IM x 1					
☐ Asymptomati☐ Symptomatic		☐ Cervix		☐ Azithromycin: ☐ 1 g				☐ 2.4 MU IM x 3					
Pelvic Inflamr		☐ Urethra☐ Urine		☐ Doxycycline: ☐ 100 mg BID x 7 days☐ Levofloxacin: ☐ 500 mg daily x 7 days			[	Doxycycline: 100 mg BID x 14 days					
☐ Ophthalmia		Rectum		Other:				☐ 100 mg BID x 28 days					
☐ Other Complications:		☐ Pharynx						Benzathine ☐ 50,000 units/kg IM x 1 PCN-G: ☐ 50,000 units/kg IM x 3			•		
		☐ Vagina ☐ Ocular							queou			1 MU/day	_
Date Tested:		Other:	:	Date Preso	cribed:				rystalli			0-14 days	IV
HERPES SIMPLE	X			ОТ	HER D	ISEASES		F	enicilli	n G:			
DIAGNOSIS		LABORATORY CO	NFIRMAT		Chanci			(	ther: _				
☐ Genital (initial infection only) ☐ Yes☐ Neonatal☐ No			☐ Granuloma Inguinale☐ Lymphogranuloma Venereum				[	Date Prescribed:					
	ATMENT PLAN	(check one or m	nore opti		_,	-8							
		treatment by eithe			-persor	or by pre	scribing medicat	ion for pat	ents to	give to th	heir s	ex partne	rs (see side 2
for additional information).													
☐ Patient-delivered treatment* - Number of partners for whom provider prescribed or provided expedited partner therapy (EPT) medication pack to be delivered by the patient to their partner(s): *Patient-delivered treatment is not recommended for men who have sex with men or patients with syphilis													
REPORTING CLINIC INFORMATION													
DATE	FACILITY NA	ME				DIAGN	IOSING CLINICIA	AN					
ADDRESS					CI	ТҮ			STATE		Z	IP	
PERSON COMPLETING FORM				TELEPH	HONE			EMAI	L				

#### PARTNER MANAGEMENT PLAN INSTRUCTIONS

## **Gonorrhea or Chlamydia Infection: Partner Treatment**

All partners should be treated as if they are infected.

The Washington State Department of Health strongly encourages providers to take responsibility to ensure partner treatment for heterosexuals, by examining and treating all patient's sex partners from the previous 60 days.

If an examination is not possible, providers should offer medication for all sex partners whom patients are able to contact.

Island County Health Department may be able to provide free medication to your patient to give their partner(s), if resources permit. Please contact your local health jurisdiction to report cases and inquire about partner management resources, possibly including EPT medications.

Island County Health Department recommends you refer all MSM patients and all patients with syphilis or newly diagnosed HIV to the health department for help notifying partners to ensure that partners receive medication; the opportunity to test for HIV, syphilis, gonorrhea, and chlamydia; and evaluation for HIV Pre-Exposure Prophylaxis (PrEP). Please inform the patient that the health department will contact them to assist with partner notification.

Although the Health Department requests that you refer patients with these risks to us, we also ask that you make every effort to help patients assure that their partners are treated.

Complete the partner management plan on the Confidential Sexually Transmitted Infection Case Report FAX form to define a partner management plan.

For copies of this case report or questions on how to fill it out, call the Island County Health Department: (360) 221-8482.

## Other STIs: Partner Treatment

All patients with infectious syphilis, chancroid, LGV, or granuloma inguinale are routinely contacted by public health staff. Patients diagnosed with genital herpes should be advised to notify their sex partners and should be informed that their partners should contact their provider for testing. Per CDC treatment guidelines, sex partners of patients who are diagnosed with early syphilis (primary, secondary, or early latent) and may be incubating disease should be treated regardless of test results. Alternative treatment for penicillin allergy among non-pregnant patients, such as an appropriate dosage of doxycycline, can also be found in the guidelines.

## RECOMMENDED REGIMENS FOR ANTIMICROBIALS LISTED ON REPORTS\*

## **GONORRHEA -- Uncomplicated**

Ceftriaxone 500 mg IM as a single dose for persons weighing < 150 kg (330 lbs), or 1 g IM as a single dose for persons weighing > 150 kg (330 lbs) $^{\dagger}$ 

## Alternatives for uncomplicated infections of the cervix, urethra, or rectum: ‡

Gentamicin 240 mg IM as a single dose PLUS azithromycin 2 g PO as a single dose  $\bf OR$  Cefixime 800 mg orally as a single  $\bf dose^{\dagger}$ 

- † If treating with ceftriaxone or cefixime, and chlamydia infection has not been excluded, providers should treat for chlamydia with doxycycline 100 mg PO BID for 7 days. During pregnancy, azithromycin 1 g PO as a single dose is recommended to treat chlamydia.
- <sup>‡</sup> Ceftriaxone is the only recommended treatment for pharyngeal gonorrhea. Consult an infectious disease provider or other STI expert for assistance if alternative treatment is required.

#### **CHLAMYDIA** -- Uncomplicated

Doxycycline 100 mg PO BID for 7 days **OR**Azithromycin 1g PO as a single dose

#### Alternatives:

Erythromycin (base) 500 mg PO QID for 7 days  ${\bf OR}$ 

Ethylsuccinate 800 mg PO QID for 7 days OR

Ofloxacin 300 mg PO BID for 7 days OR

Levofloxacin 500 mg PO for 7 days

#### SYPHILIS -- PRIMARY, SECONDARY, OR EARLY LATENT (<1 YEAR)

Benzathine penicillin G 2.4 million units IM in a single dose

## **SYPHILIS -- LATE OR UNKNOWN DURATION**

Benzathine penicillin G 2.4 million units IM for 3 doses at 1 week intervals

DOH 347-102, updated 12/14/2022. For persons with disabilities, this document is available on request in other formats. To submit a request, please call 1-800-525-0127 (TDD/TTY 1-800-833-6388).

<sup>\*</sup> Refer to "STD Diagnostic and Treatment Guidelines" or the Centers for Disease Control and Prevention's (CDC's) website (<a href="https://www.cdc.gov/std/treatment/default.htm">https://www.cdc.gov/std/treatment/default.htm</a>) for further information on treating pregnant patients, infections of the pharynx, patients with allergies, treatment of infants, and other details.

## **List of Preferred Languages:**

Instructions: Complete the Preferred Language section if the patient's preferred language is not English. Patient's preferred language shall be identified by the patient and reported using one of the below categories.

## **Language Identity Codes:**

(L18) Karen	(L35) Sign languages
(L19) Khmer/Cambodian	(L36) Somali
(L20) Kinyarwanda	(L37) Spanish/Castilian
(L21) Korean	(L38) Swahili/Kiswahili
(L22) Kosraean	(L39) Tagalog
(L23) Lao	(L40) Tamil
(L24) Mandarin	(L41) Telugu
(L25) Marshallese	(L42) Thai
(L26) Mixteco	(L43) Tigrinya
(L27) Nepali	(L44) Ukrainian
(L28) Oromo	(L45) Urdu
(L29) Panjabi/Punjabi	(L46) Vietnamese
(L30) Pashto	(L77) Other language
(L31) Portuguese	(L88) Patient declined to respond
(L32) Romanian/Rumanian	(L99) Unknown
	(L19) Khmer/Cambodian (L20) Kinyarwanda (L21) Korean (L22) Kosraean (L23) Lao (L24) Mandarin (L25) Marshallese (L26) Mixteco (L27) Nepali (L28) Oromo (L29) Panjabi/Punjabi (L30) Pashto (L31) Portuguese

(L33) Russian

(L34) Samoan

## **Race Category and Identity Instructions:**

Instructions: The patient's race may either be reported in the general Race Category section or the Extended Race section on page 1 of the case report. When completing the Extended Race section, please report using the codes provided in the list below. If the patient self-identifies as more than one race, each race code shall be reported within the extended race section. Unknown race can be documented within either one of the race sections.

## **Extended Race Codes:**

(L16) Hmong

(L17) Japanese

(R01) Afghan	(R22) Fijian	(R43) Mexican/Mexican American	(R64) Tongan
(R02) Afro-Caribbean	(R23) Filipino	(R44) Middle Eastern	(R65) Ugandan
(R03) Alaska Native	(R24) First Nations	(R45) Mien	(R66) Ukrainian
(R04) American Indian	(R25) Guamanian or Chamorro	(R46) Moroccan	(R67) Vietnamese
(R05) Arab	(R26) Hmong/Mong	(R47) Native Hawaiian	(R68) White
(R06) Asian	(R27) Indigenous-Latina/o/x	(R48) Nepalese	(R69) Yemeni
(R07) Asian Indian	(R28) Indonesian	(R49) North African	(R77) Other race
(R08) Bamar/Burman/Burmese	(R29) Iranian	(R50) Oromo	(R99) Unknown
(R09) Bangladeshi	(R30) Iraqi	(R51) Pacific Islander	
(R10) Bhutanese	(R31) Japanese	(R52) Pakistani	
(R11) Black or African American	(R32) Jordanian	(R53) Puerto Rican	
(R12) Central American	(R33) Karen	(R54) Romanian/Rumanian	
(R13) Cham	(R34) Kenyan	(R55) Russian	
(R14) Chicana/o or Chicanx	(R35) Khmer/Cambodian	(R56) Samoan	
(R15) Chinese	(R36) Korean	(R57) Saudi Arabian	
(R16) Congolese	(R37) Kuwaiti	(R58) Somali	
(R17) Cuban	(R38) Lao	(R59) South African	
(R18) Dominican	(R39) Lebanese	(R60) South American	
(R19) Egyptian	(R40) Malaysian	(R61) Syrian	
(R20) Eritrean	(R41) Marshallese	(R62) Taiwanese	
(R21) Ethiopian	(R42) Mestizo	(R63) Thai	